Cassandra Pardini, PharmD

Most Recent Articles by Cassandra Pardini, PharmD

HCV Treatment Linked to Reduced Risk of Incident CVD Events

By Nov 15, 2018

ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.

Hepatocellular Carcinoma Risk Following Antiviral Therapy for HCV Examined

By Nov 15, 2018

The retrospective study aimed to determine the risk of incident, or de novo, HCC following different regimens of antiviral therapy.

Does Obesity Impact Virological Response in HCV Patients on DAA Therapy?

By Nov 14, 2018

The review analyzed 168 patients treated with an oral DAA at a single center from 2015 to 2017.

Direct-Acting Antiviral Therapy Uptake Examined Among HCV Patients

By Nov 14, 2018

The study utilized data from the Chronic Hepatitis Cohort Study, an observational cohort study, to assess demographic and clinical characteristics associated with DAA use.

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

By Nov 13, 2018

The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).

More Articles by Cassandra Pardini, PharmD